Trial
NCT03608501
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Multiple Myeloma
Intervention
Ixazomib
Why stopped
Business decision (no safety or efficacy concerns)
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-14